Harbour Investments’s Orchestra BioMed OBIO Stock Holding History

Harbour Investments’s Portfolio OBIO Stock Details OBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,988	Closed	-$8.25K	–	4747
2025 Q4	$8.25K	Hold	1,988	–	–	﹤0.01%	2831
2025 Q3	$4.93K	Hold	1,988	–	–	﹤0.01%	2993
2025 Q2	$5.33K	Hold	1,988	–	–	﹤0.01%	2852
2025 Q1	$8.51K	Hold	1,988	–	–	﹤0.01%	2597
2024 Q4	$7.95K	Buy	+1,988	New	+$10.7K	﹤0.01%	2554
2024 Q3	–	Sell	-6,900	Closed	-$56.2K	–	3453
2024 Q2	$56.2K	Hold	6,900	–	–	﹤0.01%	1504
2024 Q1	$36.4K	Buy	6,900 +3,400	+97%	+$23K	﹤0.01%	1677
2023 Q4	$32K	Hold	3,500	–	–	﹤0.01%	1654
2023 Q3	$30.5K	Buy	+3,500	New	+$23.5K	﹤0.01%	1565
2021 Q4	–	Sell	-3,000	Closed	-$30K	–	3353
2021 Q3	$30K	Hold	3,000	–	–	﹤0.01%	2073
2021 Q2	$31K	Buy	3,000 +1,000	+50%	+$10.3K	﹤0.01%	2078
2021 Q1	$22K	Buy	+2,000	New	+$24.4K	﹤0.01%	2161

Other funds holding OBIO

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Harbour Investments's OBIO Position: Q1 2026 in Review

Harbour Investments sold out of Orchestra BioMed (OBIO) in Q1 2026, closing a stake of 1,988 shares — an estimated $8.25K sold.

Harbour Investments first reported a position in OBIO in Q1 2021 and held it in 12 quarters. The position peaked at $56.2K in Q2 2024. 65 funds tracked by Wall St. Rank hold OBIO as of Q1 2026.

Harbour Investments reported no remaining Orchestra BioMed position as of Q1 2026 after selling out during the quarter.
Harbour Investments sold 1,988 Orchestra BioMed shares in Q1 2026, an estimated $8.25K.
Harbour Investments first reported a position in Orchestra BioMed in Q1 2021 and held it in 12 quarters.
Harbour Investments's Orchestra BioMed position peaked at $56.2K in Q2 2024.
65 funds tracked by Wall St. Rank held Orchestra BioMed as of Q1 2026.

Based on Harbour Investments's 13F filing for Q1 2026, filed 15 May 2026.